Fig. 5: ZLDI-8 increases in vivo antitumor effect of Sorafenib on LM-3 cells’ subcutaneous growth. | Cell Death & Disease

Fig. 5: ZLDI-8 increases in vivo antitumor effect of Sorafenib on LM-3 cells’ subcutaneous growth.

From: Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells

Fig. 5

LM-3 cells were seeded into nude mice to form subcutaneous tumors. a–c The anti-tumor activity of ZLDI-8 and Sorafenib were measured in xenograft nude mice. The results were shown as photographs (a), tumor volumes (b) or tumor weight (c). d The expression of a proliferation marker, Ki67, was identified by western blot experiments. *p < 0.05 vs. Sorafenib or control; *p < 0.05 vs. ZLDI-8 or control

Back to article page